In the rapidly changing pharmaceutical industry, CMOs and CDMOs are crucial in speeding up the production of life-saving medications. With the global CMO market projected to reach $57.34 billion by 2032, more pharmaceutical companies are outsourcing manufacturing to optimize operations, minimize capital expenditure, and gain access to specialized expertise. This approach allows them to focus on innovation and drug development while ensuring high standards of manufacturing quality.
 
Despite the many advantages of pharma/CMO partnerships, the operating landscape is becoming increasingly intricate. Global uncertainties, evolving regulations, sustainability pressures and the push for digital transformation have heightened the complexity. Additionally, challenges like pricing, contract negotiations, and meeting delivery expectations make selecting the right partner more difficult than ever.
 
Attend Pharma IQ’s Pharma Contract Manufacturing Conference uncovered strategies for building and sustaining effective CMO/pharma partnerships in April 2025 as our attendees welcomed practical solutions to key business challenges, including real-world case studies of successful collaborations.